It’s been quite some time since we last touched upon Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) here on Street Register, and quite a bit has transpired in the way of updates from the company as well as some very interesting activity on the chart of late.
Like many cannabis related domestic stocks, CNBX found difficulty in early 2018, and has only just begun to turn things around from the stock side of things, hitting bottom at the end of February and being on a pretty convincing recovery so far this month.
Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) also has some important dates coming up as recently reported, Dr. Moran Grinberg, Cannabics’ Vice President of Research & Development, will speak at the Annual CannaTech Conference to be held in Tel-Aviv, Israel, March 19th-20th. CannaTech is a yearly conference of acknowledged leaders in science, research, medicine and government policy relating to medical cannabis. Dr. Grinberg is appearing as a Key Note speaker for the Session “Bringing Personalized Cannabinoid-based Medicine to the World”.
In her presentation, Dr. Grinberg will discuss the development of recent cancer diagnostics tools in conjunction with cannabinoid medicine. By utilizing state of the art High Throughput Screening technological systems and machine learning platforms, Cannabics aims to deliver precise data regarding the efficacy of various cannabinoid compounds on specific cancer types. (Source: PR Newswire)
In other recent news, the company appointed Yasha Borstein as the company’s Chief Data Officer. With extensive experience spanning big data analytics, machine learning, AI and software development alongside an extended track record in enterprise risk management, Borstein will oversee the design and implementation of a data governance policy for the company.
At the company’s R&D base in Israel, Cannabics is conducting scientific research on cannabinoid formulations to deliver innovative diagnostic procedures for screening cancer. Utilizing advanced detection systems and personalized bioinformatics tools, the biotech company is engaged in delivering supportive data upon which cancer patients and doctors can make informed choices about treatments and possible side effects.
“My challenge is to maximize the value of the highly sensitive data generated by Cannabics as well as ensuring the highest standards of regulatory health compliance and data governance,” says Borstein. “The role presents an exciting opportunity to assist in the advancement of a new approach to cancer Theranostics”.
“We’re delighted to welcome Yasha to the team as we continue to utilize the latest technologies to conduct research, and collect insightful data that deepens our knowledge and expands our IP portfolio,” said Cannabics newly appointed CEO Eyal Barad. “We believe we have engaged the very best and brightest scientists to explore the use of bioinformatic tools to support personalized cannabinoid-based treatments and help combat one of the leading causes of death in our time.”
Cannabics will be moving their entire R&D operation into a custom-designed, state of the art Theranostics laboratory in Rehovot, Israel,, set to open in the coming months.
Yasha Borstein’s appointment complements Cannabics’ executive leadership team alongside a distinguished advisory board including Dr. Gil Feiler as Business Development Advisor, Dr. Tal Mofkadi as Financial Advisor, Dr. Ariely-Portnoy – Advisor on Pharmaceutical Regulation, Validation & Quality and Amos Toren M.D Ph.D. as Medical Advisor. (Source: PR Newswire)
It remains to be seen if the new appointments will have any measured effect on the future of CNBX, but for now, as we mentioned above, the stock itself has undergone a recent turnaround that we are very interested in continuing to track. We’ll stay up on any further developments with CNBX and pass them along to you! Stay locked on StreetRegister.com and be sure you’re signed up for our 100% free smallcap newsletter. It’s as easy as that! Simply submit your primary active email address in the box below. Subscribe now!
Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in CNBX stock, short or long.